1Chobanian AV,Bakris GL,Black HR,et al.The seventh report of the joint national committee on the detection,eevaluation,and treatment of high blood pressure:The JNC 7 report[J].JAMA,2003,289:2560-2572.
2Allhat Collaborative Research Group.Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic:The antihypertensive.and lipid-lowering treatment to prevent heart attack trial (ALLHAT)[J].JAMA,2002,288:1981-1997.
3Cuspidi C,Macca G,Sampieri L,et al.High prevalence of cardiac and extracardiac organ damage in refractory hypertension[J].J Hypertension,2001,19:2063-2070.
4Veglio F,Rabbia F,Riva P,et al.Ambulatory blood pressure monitoring and clinical characteristics of the true and white-coat resistant hypertension[J].Clin Exp Hypertension,2001,23:203-211.
5Staessen JA,Hond ED,Celis H,et al.Antihypertensive treatment based on blood pressure measurement at home or in the physician' s office:A randomized controlled trial[J].JAMA,2004,291:955-964.
7Bumier M,Schneider MP,Chioléro A,et al.Electronic compliance monitoring in resistant hypertension:The basis for rational therapeutic decisions[J].J Hypertension,2001,19:335-341.
8Garg JP,Elliott WJ,Folker A,et al.Resistant hypertension revisited:A comparison of two university-based cohorts[J].Am J Hypertension,2005,18:619-626.
9Whelton A,Fort JG,Puma JA,et al.Cyclooxygenase-2 specific inhibitors and cardiorenal function:A randomized,controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients[J].Am J Ther,2001,8:85-95.
